Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

This study has been terminated.
(Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )
ClinicalTrials.gov Identifier:
NCT01920477
First received: July 3, 2013
Last updated: May 12, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: May 2021
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)